Women in Biotech - Cambridge Edition

Diversity challenges in the workplace

This September we are taking our successful Women in Biotech series to Cambridge, where we look forward to engaging with attendees to inspire more people to tackle diversity challenges within their organisations.

For this edition of the series we are encouraging women in the sector to bring a male colleague with them to the event. Nb. everyone planning to attend will need to register for the event.

We will be joined by some excellent speakers for a panel discussion, chaired by Sally Shorthose, which will focus on diversity challenges and how to address them in the working environment. 

We look forward to seeing you at the Babraham Research Campus for an evening of enlightening discussion and networking.


17.00 - 17.30   Registration and networking
17:30 - 17:40   Welcome
17.40 - 18.30   Speaker discussion and Q&A
18.30 - 19.30   Networking and drinks


Cambridge Building
Babraham Research Campus
CB22 3AT


Sally Shorthose


Bird & Bird

Sally has wealth of experience working with businesses at the cutting edge of research and technology and whose intellectual property is of prime importance.
Sally is one of our leading intellectual property (IP) partners. She provides a full range of intellectual property commercial advice and support to her clients, including licensing, partnering and exploitation agreements, research, development and marketing collaborations. She also frequently advises clients on regulatory and ‘freedom to operate’ matters, and manages significant due diligence matters. As a transactional intellectual property lawyer, she provides advice in relation to the protection and exploitation of a full range of IP rights, both in stand alone transactions and as part of an acquisition, divestment or investment activity.
Sally speaks on a variety of IP and regulatory life sciences topics at conferences and contributes to many leading publications; she is also the editor of the The Guide to EU Pharmaceutical Regulatory Law (published by Kluwer Law International), which is written entirely by the team at Bird & Bird with contributions from many offices. Sally is also leading the Bird & Bird Brexit Steering Committee; she gives regular talks and has published several articles on the implications of Brexit for the life sciences and medical devices industries.

Mihriban Tuna

Senior Vice President, Drug Discovery


Mihriban has been with F-star since 2008 and currently holds the position of SVP Drug Discovery, leading all internal and collaborative mAb2 discovery programmes. Prior to F-star she spent 6 years at Domantis/GSK Biopharm where she was involved in the discovery of domain antibodies, as well as technology development. Mihriban made the transition from academic research to industry after completing her PhD with Professor Dek Woolfson at the University of Sussex where she focused on the structure/stability engineering and design of small globular proteins.

Dr Karolina Zapadka

Head of Babraham Accelerator

Babraham Research Campus

Karolina joined the Babraham Research Campus in 2018 where she co-founded and successfully delivered the Accelerate@Babraham initiative. As part of this, Karolina launched the first life science acceleration programme for early stage ventures combining access to lab space, mentoring from business and scientific experts and access to investors in the Cambridge Cluster.

Karolina’s strong interest in life science entrepreneurship and expediting treatment to patients led her to join the Oxbridge Biotech Roundtable in 2013 where she launched the OneStart competition. She then co-founded and became Chief of Staff at the Global Innovation Forum and IMAGINE IF! accelerator in 2014. This experience gave her strong relationships with various partners regionally, nationally and internationally – including investors, academic leaders and CEO’s of biotech and big pharmaceutical companies.

Karolina has over 7 years experience in building healthcare companies within the Cambridge Cluster. She was pivotal in securing over £7.5 million for a number of British early stage ventures (pre-seed and seed stage) from a stellar syndicate of investors (business angels and VCs). She started her career as a scientist in protein and peptide therapeutics at a leading biopharmaceutical company developing a portfolio of products to enable improved treatments for diabetes care. Karolina completed a PhD in Biophysics at the University of Cambridge and carried out her Postdoctoral work at AstraZeneca.


BIA members - £25 + VAT
Non-members - £35 + VAT

BIA emerging companies or early stage non-member companies (in a company with less than 10 employees) or a university researcher - £20 + VAT *

*Please email biaevents@bioindustry.org to receive this rate

By registering to this event you accept our Terms & Conditions

Terms & Conditions


Women in Biotech Series Sponsor


BIA Annual Supporters